Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina

Autores
Sacchi, Osvaldo Jorge; Kaiser, L.; Riestra, M. P.; Zapata, Maria Patricia; Rodriguez Echandia, Eduardo Luciano
Año de publicación
2015
Idioma
español castellano
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Las benzodiazepinas (BZDs) son fármacos ampliamente utilizados a nivel global como ansiolíticos de acción rápida, tanto en trastornos de ansiedad primaria (fobias, crisis de pánico, ansiedad generalizada) como secundaria (factores ambientales, estrés, acontecimientos vitales, enfermedades orgánicas ansió­ genas y otras), también como sedantehipnóticos y para otras aplicaciones. Sus beneficios en estos cuadros son indudables pero su riesgo es también alto. Todas pueden producir tolerancia y dependencia física cuando se las utiliza a mediano y largo plazo, por lo que su prescripción debe estar acotada a unas pocas semanas, evitando la prescripción crónica, y utilizando la menor dosis posible.
This is an analytical retrospective study on benzodiazepines (BZDs) prescription in the DAMSU´s affiliation along years 2007 and 2012 to identify demography of users, epidemiology of all dispensed ansiolytic BZDs and the modalities of their use. The total prescription orders delivered in these years were recorded according to the DURG methodology. The total mg/user/year and the DDDs/ year of the BZDs dispensed to each user were considered as a measure of utilization. The total DAMSU´s affiliation was 24684 in 2007, this grown to 26097 in 2012. The BZDs users were 15.4% of the total affiliation in 2007 and 17.4% in 2012. In both years, almost 90% of users aged 40 to 80 years with a maximal prevalence between 60 and 79 years. A 63.8 of users were females, so males rounded 36% only (difference P<0.01). In 2007, 8 BZDs were prescribed and the ranking was alprazolam> clonazepam>diazepam>.lorazepam>broma zepam>chlorazepate>clobazan>oxazepam. In 2012 the same BZDs were prescribed but clonazepam headed the ranking followed by alprazolam, the rest was similar. Grouping the users of clonazepam together with those of alprazolam they reached the 79.7% of the total users of BZDs in 2007 and the 85.3% in 2012. As to the modalities of BZDs consumption, the users with a dispensation up to the 6th part of the corresponding DDD/year were grouped as BZD “low users”. The clonazepam users dispensed with 1 or 2 prescription orders in the year were more than 64% and the amount of the low diazepam users was 51%. Percentages of low users of the rest of BZDS were less than 30%. This group was considered as occasional users, then not dependent of BZDs consumption. Were considered as “intermediate consumption users” those that were dispensed with up to 66% of the corresponding DDD/ year; these would represent the frequent utilization users. The group identified as “high utilization users” was dispensed with about the corresponding DDD/year. This comprised the almost permanent users in doses equivalent to those indicated in ATC. Finally, the group enclosing the “excessive utilization users” was the one of permanent users with doses much higher than the corresponding DDD/year. In this group the percentage of alprazolam users (22.5%) and lorazepam (17%) significantly surpassed those of the rest of BZDs. Joining together the percentages of “high” and “excessive” users of clonazepam (6.7% only) and diazepam (17.0%) these were significantly lower than those of the rest of BZDs. Results suggest that these two BZDs have the less addictive potential, and would provide less consumption dependence than the other BZDs.
Fil: Sacchi, Osvaldo Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Kaiser, L.. Universidad Nacional de Cuyo; Argentina
Fil: Riestra, M. P.. Universidad Nacional de Cuyo; Argentina
Fil: Zapata, Maria Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Rodriguez Echandia, Eduardo Luciano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Materia
Benzodiazepinas
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/41887

id CONICETDig_9cc2d88230ad8c74f759468ae43cb44d
oai_identifier_str oai:ri.conicet.gov.ar:11336/41887
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de ArgentinaSacchi, Osvaldo JorgeKaiser, L.Riestra, M. P.Zapata, Maria PatriciaRodriguez Echandia, Eduardo LucianoBenzodiazepinashttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Las benzodiazepinas (BZDs) son fármacos ampliamente utilizados a nivel global como ansiolíticos de acción rápida, tanto en trastornos de ansiedad primaria (fobias, crisis de pánico, ansiedad generalizada) como secundaria (factores ambientales, estrés, acontecimientos vitales, enfermedades orgánicas ansió­ genas y otras), también como sedantehipnóticos y para otras aplicaciones. Sus beneficios en estos cuadros son indudables pero su riesgo es también alto. Todas pueden producir tolerancia y dependencia física cuando se las utiliza a mediano y largo plazo, por lo que su prescripción debe estar acotada a unas pocas semanas, evitando la prescripción crónica, y utilizando la menor dosis posible.This is an analytical retrospective study on benzodiazepines (BZDs) prescription in the DAMSU´s affiliation along years 2007 and 2012 to identify demography of users, epidemiology of all dispensed ansiolytic BZDs and the modalities of their use. The total prescription orders delivered in these years were recorded according to the DURG methodology. The total mg/user/year and the DDDs/ year of the BZDs dispensed to each user were considered as a measure of utilization. The total DAMSU´s affiliation was 24684 in 2007, this grown to 26097 in 2012. The BZDs users were 15.4% of the total affiliation in 2007 and 17.4% in 2012. In both years, almost 90% of users aged 40 to 80 years with a maximal prevalence between 60 and 79 years. A 63.8 of users were females, so males rounded 36% only (difference P<0.01). In 2007, 8 BZDs were prescribed and the ranking was alprazolam> clonazepam>diazepam>.lorazepam>broma zepam>chlorazepate>clobazan>oxazepam. In 2012 the same BZDs were prescribed but clonazepam headed the ranking followed by alprazolam, the rest was similar. Grouping the users of clonazepam together with those of alprazolam they reached the 79.7% of the total users of BZDs in 2007 and the 85.3% in 2012. As to the modalities of BZDs consumption, the users with a dispensation up to the 6th part of the corresponding DDD/year were grouped as BZD “low users”. The clonazepam users dispensed with 1 or 2 prescription orders in the year were more than 64% and the amount of the low diazepam users was 51%. Percentages of low users of the rest of BZDS were less than 30%. This group was considered as occasional users, then not dependent of BZDs consumption. Were considered as “intermediate consumption users” those that were dispensed with up to 66% of the corresponding DDD/ year; these would represent the frequent utilization users. The group identified as “high utilization users” was dispensed with about the corresponding DDD/year. This comprised the almost permanent users in doses equivalent to those indicated in ATC. Finally, the group enclosing the “excessive utilization users” was the one of permanent users with doses much higher than the corresponding DDD/year. In this group the percentage of alprazolam users (22.5%) and lorazepam (17%) significantly surpassed those of the rest of BZDs. Joining together the percentages of “high” and “excessive” users of clonazepam (6.7% only) and diazepam (17.0%) these were significantly lower than those of the rest of BZDs. Results suggest that these two BZDs have the less addictive potential, and would provide less consumption dependence than the other BZDs.Fil: Sacchi, Osvaldo Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Kaiser, L.. Universidad Nacional de Cuyo; ArgentinaFil: Riestra, M. P.. Universidad Nacional de Cuyo; ArgentinaFil: Zapata, Maria Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Rodriguez Echandia, Eduardo Luciano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaEdiciones Médicas del Sur2015-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/41887Sacchi, Osvaldo Jorge; Kaiser, L.; Riestra, M. P.; Zapata, Maria Patricia; Rodriguez Echandia, Eduardo Luciano; Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina; Ediciones Médicas del Sur; La Prensa Médica Agentina; 101; 2; 4-2015; 89-950032-745XCONICET DigitalCONICETspainfo:eu-repo/semantics/altIdentifier/url/http://www.prensamedica.com.ar/rev_arc.htmlinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:02:35Zoai:ri.conicet.gov.ar:11336/41887instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:02:35.802CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
title Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
spellingShingle Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
Sacchi, Osvaldo Jorge
Benzodiazepinas
title_short Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
title_full Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
title_fullStr Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
title_full_unstemmed Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
title_sort Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina
dc.creator.none.fl_str_mv Sacchi, Osvaldo Jorge
Kaiser, L.
Riestra, M. P.
Zapata, Maria Patricia
Rodriguez Echandia, Eduardo Luciano
author Sacchi, Osvaldo Jorge
author_facet Sacchi, Osvaldo Jorge
Kaiser, L.
Riestra, M. P.
Zapata, Maria Patricia
Rodriguez Echandia, Eduardo Luciano
author_role author
author2 Kaiser, L.
Riestra, M. P.
Zapata, Maria Patricia
Rodriguez Echandia, Eduardo Luciano
author2_role author
author
author
author
dc.subject.none.fl_str_mv Benzodiazepinas
topic Benzodiazepinas
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Las benzodiazepinas (BZDs) son fármacos ampliamente utilizados a nivel global como ansiolíticos de acción rápida, tanto en trastornos de ansiedad primaria (fobias, crisis de pánico, ansiedad generalizada) como secundaria (factores ambientales, estrés, acontecimientos vitales, enfermedades orgánicas ansió­ genas y otras), también como sedantehipnóticos y para otras aplicaciones. Sus beneficios en estos cuadros son indudables pero su riesgo es también alto. Todas pueden producir tolerancia y dependencia física cuando se las utiliza a mediano y largo plazo, por lo que su prescripción debe estar acotada a unas pocas semanas, evitando la prescripción crónica, y utilizando la menor dosis posible.
This is an analytical retrospective study on benzodiazepines (BZDs) prescription in the DAMSU´s affiliation along years 2007 and 2012 to identify demography of users, epidemiology of all dispensed ansiolytic BZDs and the modalities of their use. The total prescription orders delivered in these years were recorded according to the DURG methodology. The total mg/user/year and the DDDs/ year of the BZDs dispensed to each user were considered as a measure of utilization. The total DAMSU´s affiliation was 24684 in 2007, this grown to 26097 in 2012. The BZDs users were 15.4% of the total affiliation in 2007 and 17.4% in 2012. In both years, almost 90% of users aged 40 to 80 years with a maximal prevalence between 60 and 79 years. A 63.8 of users were females, so males rounded 36% only (difference P<0.01). In 2007, 8 BZDs were prescribed and the ranking was alprazolam> clonazepam>diazepam>.lorazepam>broma zepam>chlorazepate>clobazan>oxazepam. In 2012 the same BZDs were prescribed but clonazepam headed the ranking followed by alprazolam, the rest was similar. Grouping the users of clonazepam together with those of alprazolam they reached the 79.7% of the total users of BZDs in 2007 and the 85.3% in 2012. As to the modalities of BZDs consumption, the users with a dispensation up to the 6th part of the corresponding DDD/year were grouped as BZD “low users”. The clonazepam users dispensed with 1 or 2 prescription orders in the year were more than 64% and the amount of the low diazepam users was 51%. Percentages of low users of the rest of BZDS were less than 30%. This group was considered as occasional users, then not dependent of BZDs consumption. Were considered as “intermediate consumption users” those that were dispensed with up to 66% of the corresponding DDD/ year; these would represent the frequent utilization users. The group identified as “high utilization users” was dispensed with about the corresponding DDD/year. This comprised the almost permanent users in doses equivalent to those indicated in ATC. Finally, the group enclosing the “excessive utilization users” was the one of permanent users with doses much higher than the corresponding DDD/year. In this group the percentage of alprazolam users (22.5%) and lorazepam (17%) significantly surpassed those of the rest of BZDs. Joining together the percentages of “high” and “excessive” users of clonazepam (6.7% only) and diazepam (17.0%) these were significantly lower than those of the rest of BZDs. Results suggest that these two BZDs have the less addictive potential, and would provide less consumption dependence than the other BZDs.
Fil: Sacchi, Osvaldo Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Kaiser, L.. Universidad Nacional de Cuyo; Argentina
Fil: Riestra, M. P.. Universidad Nacional de Cuyo; Argentina
Fil: Zapata, Maria Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Rodriguez Echandia, Eduardo Luciano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
description Las benzodiazepinas (BZDs) son fármacos ampliamente utilizados a nivel global como ansiolíticos de acción rápida, tanto en trastornos de ansiedad primaria (fobias, crisis de pánico, ansiedad generalizada) como secundaria (factores ambientales, estrés, acontecimientos vitales, enfermedades orgánicas ansió­ genas y otras), también como sedantehipnóticos y para otras aplicaciones. Sus beneficios en estos cuadros son indudables pero su riesgo es también alto. Todas pueden producir tolerancia y dependencia física cuando se las utiliza a mediano y largo plazo, por lo que su prescripción debe estar acotada a unas pocas semanas, evitando la prescripción crónica, y utilizando la menor dosis posible.
publishDate 2015
dc.date.none.fl_str_mv 2015-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/41887
Sacchi, Osvaldo Jorge; Kaiser, L.; Riestra, M. P.; Zapata, Maria Patricia; Rodriguez Echandia, Eduardo Luciano; Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina; Ediciones Médicas del Sur; La Prensa Médica Agentina; 101; 2; 4-2015; 89-95
0032-745X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/41887
identifier_str_mv Sacchi, Osvaldo Jorge; Kaiser, L.; Riestra, M. P.; Zapata, Maria Patricia; Rodriguez Echandia, Eduardo Luciano; Modalidades de utilización de benzodiazepinas ansiolíticas en los afiliados a un Departametno de Asistencia Médico Social Universitaria de Argentina; Ediciones Médicas del Sur; La Prensa Médica Agentina; 101; 2; 4-2015; 89-95
0032-745X
CONICET Digital
CONICET
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.prensamedica.com.ar/rev_arc.html
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Ediciones Médicas del Sur
publisher.none.fl_str_mv Ediciones Médicas del Sur
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613831818477568
score 13.070432